More on MRK's HIV-1 Program [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
regimen of doravirine/islatravir (DOR/ISL) in virologically suppressed adults with HIV-1 infection. The phase III MK-8591A-051 and MK-8591A-052 studies evaluated DOR/ISL (100 mg/0.25 mg) in adults with HIV-1 infection who are on different antiretroviral therapy regimens like baseline antiretroviral therapy and bictegravir/emtricitabine/tenofovir alafenamide, respectively. Data from both studies showed that treatment with DOR/ISL demonstrated non-inferiority versus comparator antiretroviral therapies in adults with virologically suppressed HIV-1, the success criteria for the primary efficacy hypothesis. However, the MK-8591A-052 study failed to meet the superiority criteria, but both studies met the primary safety objectives. Year to date, shares of Merck have declined 8.8% against the industry's growth of 4.4%. Zacks Investment Research Image Source: Zacks Investment Research More on MRK's HIV-1 Program Besides MK-8591A-051 and MK-8591A-052 studies, two other ongoing p
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know [Yahoo! Finance]Yahoo! Finance
- BMO cuts rating on Merck and Biogen, on lack of near term catalyst [Yahoo! Finance]Yahoo! Finance
- Investing in Merck (NYSE:MRK) three years ago would have delivered you a 43% gain [Yahoo! Finance]Yahoo! Finance
- Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals [Yahoo! Finance]Yahoo! Finance
- Merck & Co., Inc. (NYSE: MRK) was downgraded by analysts at BMO Capital Markets from an "outperform" rating to a "market perform" rating. They now have a $105.00 price target on the stock, down previously from $136.00.MarketBeat
MRK
Earnings
- 10/31/24 - Beat
MRK
Sec Filings
- 11/22/24 - Form 8-K
- 11/6/24 - Form 10-Q
- 11/4/24 - Form 25-NSE
- MRK's page on the SEC website